On International NASH Day 2023, join Michael Betel of the Fatty Liver Alliance as he addresses NAFLD and NASH, their prevalence and impact. Discover solutions including medical education, patient awareness, and advocacy. Learn about the Alliance's future goals.
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic steatohepatitis (NASH) with insights from Dr Giada Sebastiani, associate professor of medicine at McGill University Health Center in Canada.
Dr. Kwanten (Belgium) discusses the pathophysiological role of intrahepatic vasculature in non-alcoholic fatty liver disease (NAFLD). He mentions that portal hypertension is present in patients with NAFLD and can be evident in the early stages which is caused by intrahepatic vascular alterations. Further, he explores the different types of drugs that will help change the course of the disease.
Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.
Liver fibrosis is the major driver in liver disease progression. Prof. Romero-Gómez, Spain, reviews on NoninvasiveTests - NITs for screening, referral, and diagnosis of nonalcoholic fatty liver disease.
Dr. Jean-François Dufour (Switzerland) reviews the association between cancers and NASH, where he highlights the causes of death in NAFLD patients, in which cardiovascular diseases and non-liver cancer with 38.3% and 18.7% are identified as some of the major causes.
Dr. Marat Fudim (USA) reviews the interaction between NAFLD and Heart Failure with preserved Ejection Fraction (HFpEF), including highlights of the global prevalence rate of NAFLD.
There is a need for new biomarkers that allow the detection and quantification of liver diseases supported on the measurement of fat, iron, fibrosis, inflammation. Dr Romero-Gomez presents a state-of-the-art video on imaging biomarkers with the pros and cons for each technology. For daily practice, he also suggests a diagnosis algorithm
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Prof Rautou, France, sheds light on microvesicles, which reflect apoptosis and cell activation. He discusses what we know about microvesicles in NASH and the rationale to consider them as biomarkers in liver disease.
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES
Manage your privacy
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.